Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABA<sub>A</sub> Receptor

Martyn Wood, Veronique Daniels,1 Laurent Provins, Christian Wolff, Rafal M. Kaminski,2 and Michel Gillard

UCB Pharma, Neurosciences Therapeutic Area, Braine l’Alleud, Belgium

Received July 8, 2019; accepted October 10, 2019

ABSTRACT
Padsevonil is an antiepileptic drug (AED) candidate developed as a single molecular entity interacting with both presynaptic and postsynaptic targets. Results of in vitro and in vivo binding assays confirmed this target profile: padsevonil displayed nanomolar affinity for the three synaptic vesicle 2 protein isoforms (SV2A, B, and C) and micromolar affinity for the benzodiazepine binding site on GABA<sub>A</sub> receptors. Furthermore, padsevonil showed greater affinity for and slower binding kinetics at SV2A than the selective SV2A ligands, levetiracetam, and brivaracetam. The precise function of the proteins remains elusive; however, given their presence in secretory vesicles, it is most likely that they play a role in vesicle exocytosis, an observation substantiated by accumulating evidence (Mendoza-Torreblanca et al., 2013). SV2A knockout mice die in a matter of weeks; however, in vitro recordings of neurons from very young SV2A knockout mice reveal a reduction in the frequency and amplitude of spontaneous inhibitory postsynaptic currents, potentially indicating a negative effect on GABA release from presynaptic neurons (Crowder et al., 1999). Data from animals lacking both SV2A and SV2B suggest that the absence of these proteins leads to presynaptic Ca<sup>2+</sup> accumulation during con- current action potentials, causing abnormal increases in neurotransmitter release (Janz et al., 1999a). The overall effect is destabilization of synaptic circuits and aberrant neurotransmission (Crowder et al., 1999; Janz et al., 1999a). LEV reduces both inhibitory and excitatory postsynaptic currents in an activity-dependent manner, with the largest effect seen with the highest stimulation frequency (Meehan et al., 2012). Both LEV and

Introduction
Levetiracetam (LEV) was the first antiepileptic drug (AED) shown to exert its therapeutic activity by targeting elements of the synaptic release machinery, namely, through binding to the synaptic vesicle 2A (SV2A) protein (Lynch et al., 2004). SV2A and the other two protein isoforms—SV2B and SV2C—are integral membrane glycoproteins that are present in secretory vesicles of neurons and endocrine cells (Bartholome et al., 2017). The precise function of the proteins remains elusive; however, given their presence in secretory vesicles, it

ABBREVIATIONS: 5-HT, serotonin; AED, antiepileptic drug; BRV, brivaracetam; BZD, benzodiazepine; CB, cannabinoid; GABA<sub>A</sub>R, GABA<sub>A</sub> receptor; HEK, human embryonic kidney cell line; IL, interleukin; LEV, levetiracetam; PSL, padsevonil; SV2, synaptic vesicle protein 2; TLR, toll-like receptor.
brivaracetam (BRV), a more potent and selective SV2A ligand (Klitgaard et al., 2016), produce frequency-dependent slowing of vesicle exocytosis and recycling, and of synaptic transmission (Meehan et al., 2011, 2012; Yang et al., 2015).

The substantial evidence for the role of SV2A in the pathophysiology of epilepsy (Löschner et al., 2016; Ohno and Tokudome, 2017) and the clinical utility of SV2A ligands in the treatment of patients with epilepsy ensured that drug-discovery programs focusing on SV2 ligands continued. One strand of research involved investigating the feasibility of designing a molecule with both presynaptic and postsynaptic activity via interaction with SV2 proteins and the GABA<sub>A</sub> receptor (GABA<sub>A</sub>R), respectively. The rationale for targeting these proteins was based on observations that LEV markedly potentiated the activity of AEDs acting via GABA<sub>A</sub> transmission, notably benzodiazepines (BZDs), in several animal models resulting in an improved efficacy/safety ratio (Kaminski et al., 2009a). More recent studies have shown that SV2A dysfunction resulting from a missense mutation (L174Q) results in a selective reduction in GABA<sub>A</sub>ergic transmission, rendering animals carrying the mutation highly susceptible to seizures and markedly facilitating kindling (Tokudome et al., 2016a,b). In the subsequent rational medicinal chemistry design program, the focus was to develop a single molecule that could target SV2 proteins with high affinity and postsynaptic GABA<sub>A</sub>R<sub>s</sub>, specifically the BZD binding site, with lower marked efficacy/safety ratio (Kaminski et al., 2009a). The rationale for targeting these proteins was based on observations that LEV markedly potentiated the activity of AEDs acting via GABA<sub>A</sub> transmission, notably benzodiazepines (BZDs), in several animal models resulting in an improved efficacy/safety ratio (Kaminski et al., 2009a). More recent studies have shown that SV2A dysfunction resulting from a missense mutation (L174Q) results in a selective reduction in GABA<sub>A</sub>ergic transmission, rendering animals carrying the mutation highly susceptible to seizures and markedly facilitating kindling (Tokudome et al., 2016a,b).

In the subsequent rational medicinal chemistry design program, the focus was to develop a single molecule that could target SV2 proteins with high affinity and postsynaptic GABA<sub>A</sub>R<sub>s</sub>, specifically the BZD binding site, with lower marked efficacy/safety ratio (Kaminski et al., 2009a). More recent studies have shown that SV2A dysfunction resulting from a missense mutation (L174Q) results in a selective reduction in GABA<sub>A</sub>ergic transmission, rendering animals carrying the mutation highly susceptible to seizures and markedly facilitating kindling (Tokudome et al., 2016a,b).

**Radioisotope Tracing**

The following compounds were synthesized at UCB (Braine l’Alleud, Belgium): PSL (4(2R)-4-(2-chloro-2,2-difluoroethyl)-1-[(2-(methoxyethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)ethyl]pyrrolidin-2-one), LEV (2S-(2-oxo-1-pyrrolidinyl)butanamide), UC830889 (2S-2-(4-azidophenyl)-2-oxopyrrolidin-1-yl[butanamide], BRV (2S-2-(4R-2-oxo-4-propylpyrrolidin-1-yl) butanamide), and UCB1244283 ((4-(3,5-dimethoxyphenyl)-N-(2-methoxyphenyl)-3-methylbutanamide). For in vitro studies, compounds were dissolved in DMSO, and for in vivo studies, PSL was dissolved in 0.1% Tween 80 in NaCl (0.9%), and LEV and BRV in saline.

**Tissue and Membrane Preparations**

**Preparation of Membrane Proteins from Rat and Human Cortex.** Membrane proteins from rat cortex were prepared as described previously (Fuks et al., 2003). Briefly, after rats were sacrificed by decapitation, brains were removed rapidly and dissected on ice. All subsequent operations were performed at 4°C. Brain tissue, either rat or human cerebral cortex, was homogenized (10% w/v) in 20 mM Tris-HCl buffer (pH 7.4), containing 250 mM sucrose (buffer A) in a Potter-Elvehjem homogenizer. Homogenates were spun at 30,000 g for 15 minutes, and the pellets were resuspended in the same buffer. After incubation at 37°C for 15 minutes, membranes were washed three times using the same centrifugation protocol. Final pellets were resuspended in buffer A at a protein concentration of 10–15 mg mL<sup>-1</sup> and stored at −140°C until further use.

**Preparation of Membrane Proteins from HEK and COS-7 Cells.** Human SV2A, B, and C were expressed in HEK cells and rat GABA<sub>A</sub>R<sub>s</sub> (α1β2γ2; α2β2γ2; α5β2γ2) in COS-7 cells. Cells were subcultured in Dulbecco’s modified Eagle’s medium containing 100 mM L-glutamine and 100 mg mL<sup>-1</sup> streptomycin, supplemented with 10% fetal bovine serum, and grown in a humidified atmosphere of 5% CO<sub>2</sub> at 37°C. Confluent cells were harvested by trypsinization and pelleted by centrifugation at 1500g for 10 minutes at 4°C. The pellet was washed with ice cold PBS using the same centrifugation protocol and homogenized in a buffer containing 15 mM Tris-HCl, 1 mM EGTA, 0.5 mM EDTA, and 2 mM MgCl<sub>2</sub> (pH 7.5) supplemented with complete protease inhibitor cocktail. The homogenate was freeze-thawed twice and equilibrated at 25°C followed by a 10-minute DNase (10 U mL<sup>-1</sup>) treatment. The solution was centrifuged for 25 minutes at 40,000g and 4°C. Finally, the pellet was resuspended in buffer A at a protein concentration of 5–10 mg mL<sup>-1</sup> and stored at −140°C until further use.
Radioligand Binding Experiments

Experiments were performed as previously described (Fuchs et al., 2003). For all assays, membrane proteins (100 μg per assay for cortical membrane proteins, 70–125 μg for SV2A, 2–5 μg for SV2B, 40–60 μg for SV2C, and 75–125 μg for rat GABA_A receptor subtypes) were incubated for 120 minutes at 4°C or 60–150 minutes at 37°C in 0.5 or 2 ml of Tris-HCl buffer (50 mM, pH 7.4) containing 2 mM MgCl₂. All glass fiber filters (from Brandel Inc., Gaithersburg, MD) used in the experiments were presoaked in 0.1% polyethyleneimine.

Competition Binding Experiments. Increasing concentrations of unlabeled competing drugs were added in the presence of 0.9 or 9 nM [3H]PSL, 1 or 4 nM [3H]UCB30889 or 2 nM [3H]flunitrazepam. At the end of the incubation period, membrane-bound radioligand was recovered by rapid filtration through GF/F filters. Plates were washed rapidly three times with 0.3 ml of ice-cold Tris buffer; the total washing procedure did not exceed 10 seconds.

Kinetic Experiments. Specific [3H]PSL binding in association experiments was measured at the indicated times after addition of membrane proteins at 37°C. Dissociation was induced by the addition of 10 μM of unlabeled PSL to the association reaction mixture. Samples were filtered on GF/C filters and washed with 5 ml of ice-cold Tris buffer. Total filtration time per sample did not exceed 2 seconds.

Saturation Binding Experiments. Membrane proteins were incubated with [3H]PSL at concentrations ranging from 0.05 to 22 nM, and samples were filtered using GF/B filters. Non-specific binding was defined as residual binding observed in the presence of 10 μM unlabeled PSL for [3H]PSL, 1 mM LEV for [3H]UCB30889, or 10 μM diazepam for [3H]flunitrazepam. Radioactivity was determined by liquid scintillation.

The effect of UCB1244283, a positive allosteric modulator of SV2A, on PSL binding to SV2A was also evaluated. Studies were performed at 4°C according to the protocol described by Wood and Gillard (2017).

In Vivo Receptor Occupancy. The protocol developed by Li et al. (2006) was followed using NMRI mice instead of rats. Animals received vehicle (TWEEN/saline) or PSL (10 ml/kg body weight), administered intraperitoneally, followed 27 minutes later by tail-vein injections (2 μg/kg) of either [3H]UCB30889 (2 μCi) or [3H]flunitrazepam (1 μCi). Necks of mice were dislocated 3 minutes after injection, and whole brains were rapidly removed, weighed, and homogenized in 10 volumes of ice-cold Tris buffer. The homogenate (300 μl) was filtered over GF/C filters and washed three times with 2 ml of ice-cold Tris buffer. Retained radioactivity was counted by liquid scintillation. Studies consisted of eight treatment groups (six PSL doses, one vehicle, one UCB30889/flunitrazepam), with six mice per group.

Selectivity Studies

Selectivity of PSL for its therapeutic targets was determined using radioligand binding, receptor activation, and electrophysiological studies.

Radioligand binding studies were performed at CEREP (le Bois l’Eveque, France) and at UCB (Braine l’Alleud, Belgium) according to standard protocols. PSL was evaluated at 10 μM against a panel of various molecular targets, including ligand-gated and G-protein-coupled receptors, ion channels, transporters, and enzymes. Receptors included acetylcholine nicotinic (neuronal and muscular), GABA_A receptors, glycine, glutamate (AMPA, kainite, and NMDA), neurokinin (NK₁, NK₂, and NK₃), serotonin (5-HT₁A, 5-HT₁B, 5-HT₁D, 5-HT₂A, 5-HT₂B, 5-HT₂C, 5-HT₃, 5-HT₄, 5-HT₅A, 5-HT₅B, and 5-HT₅F), transforming growth factor β₁, opioid (δ, κ, and µ), histamine (H₁, H₂, and H₄), sigma 1 and vasopressin (V₁a) receptors. Ion channels included L- and N-type voltage-gated Ca²⁺ channels (Caᵥ1.2), voltage-gated Na⁺ channels, and Ca²⁺-activated ATP-sensitive and voltage-gated K⁺ channels. Other targets were transporters, including adenosine, norepinephrine, dopamine, GABA, and 5-HT transporters, as well as the enzymes phospholipase A₂, cyclooxygenase 1 and 2, constitutive nitric oxide synthase, catechol-O-methyl transferase, GABA transaminase, and tyrosine hydroxylase.

Receptor activation studies were conducted at Eurofins Panlabs (St. Charles, MO) using standard protocols. The ability of PSL at concentrations of 1, 3, 10, and 30 μM to activate toll-like receptors (TLR 2 and 4) on cultured human peripheral blood mononuclear cells was evaluated by measuring concentrations of specific cytokines in the culture supernatant after stimulation. Cytokines tested included interleukin (IL)-1β, IL-6, IL-10, IL-12p40, and tumor necrosis factor α.

The effects of 10 μM PSL on selected ion channels was determined at BYSYS (Witterswil, Switzerland) using standard protocols. These included endogenous Na⁺ channels expressed in N1E-115 cells; Caᵥ2.1, voltage-gated K⁺ Kᵥ7.2/7.3 channels, AMPA receptors (GRIA 1) and kainate receptors (GluK2/GluK5) expressed in Chinese hamster ovary cells; Caᵥ3.2 channels and NMDA (NR1/NR2A, NR1/NR2B) receptors expressed in HEK cells.

Functional Electrophysiological Studies

Electrophysiological recordings from GABA_A channels were performed as described previously (Ghisdal et al., 2014). Briefly, Cl⁻ currents were recorded from a Chinese hamster ovary-K1 cell line expressing the recombinant human α₁β₂γ₂ GABA_A subtype. Patch-clamp recordings were performed on a PatchXpress system (Molecular Devices, Sunnyvale, CA). During all procedures, the holding potential was set to −60 mV. Whole-cell compensation was automatically set before each experiment. Current traces were recorded by a patch-clamp amplifier (Multiclamp 700A computer-controlled patch-clamp dual headstage amplifier, Axon Instruments) at a sampling rate of 2 kHz. Recordings were performed at room temperature (−25°C).

Data Analysis

In radioligand binding studies, data were analyzed by computerized nonlinear curve-fitting methods (Graphpad Prism 5 software, San Diego, CA), according to equations describing several binding models (Molinoff et al., 1981). IC₅₀ values were corrected to Kᵢ by applying the Cheng and Prusoff equation (Cheng and Prusoff, 1973).

In electrophysiological studies, data were analyzed using DataXpress 2 software (version 2.0.4.2; Molecular Devices). The potentiation of GABA_A-evoked Cl⁻ currents in the presence of drug was determined and compared with the maximum potentiation in the presence of 1 μM zolpidem.

Results

Affinity for SV2A and the BZD Site

To determine the affinity of PSL for SV2A, the radioligand [³H]UCB30889 was used in competition experiments in human and rat cortices. This compound is an LEV analog with 20-fold greater affinity for SV2A than LEV, which makes it a suitable radioligand for labeling SV2A (Gillard et al., 2003, 2006). [³H]Flunitrazepam, a BZD with full agonist properties, was used for determining the affinity of PSL for the BZD site. PSL exhibited nanomolar affinity for SV2A labeled with [³H]UCB30889 and micromolar affinity for the BZD site labeled with [³H]flunitrazepam (Table 1). Further studies on human recombinant GABA_A subtypes (α₁β₂γ₂, α₂β₂γ₂, and α₅β₂γ₂) yielded pIC₅₀ values of 6.1 ± 0.1 (n = 4), <5 (n = 3), and 6.0 ± 0.1 (n = 3), respectively, at 4°C.

In Vivo SV2A and BZD Site Occupancy

The binding profile of PSL to SV2A and the BZD site was also characterized in vivo, where results were similar to those obtained using cortical preparations: SV2A occupancy was
observed at low doses and BZD site occupancy at higher doses, indicating a greater PSL affinity for SV2A than the BZD site. In the dose-range administered intraperitoneally in mice, PSL ED_{50} for SV2A occupancy was 0.4 μmol/kg (0.2 mg/kg; pED_{50} 6.4 mol/kg), whereas that of BZD site occupancy was markedly higher at 72 μmol/kg (36 mg/kg; pED_{50} 4.14 mol/kg) (Fig. 2).

### Binding Characteristics at SV2 Isoforms

Detailed characterization of PSL binding to the three SV2 isoforms was performed using [3H]PSL, the tritium-radiolabeled compound.

**Kinetic Experiments.** Binding kinetics of [3H]PSL were determined on human recombinant SV2 isoforms expressed in HEK cells and in human and rat cortex at 37°C (Fig. 3; Table 2). [3H]PSL association kinetics were monophasic at all protein sources. Dissociation kinetics were also monophasic for the recombinant SV2 isoforms but more complex in human and rat cortex, although no clear separation of the phases was evident.

**Saturation Binding Experiments.** Saturation binding curves of [3H]PSL on human recombinant SV2A/B/C and on human and rat cortex proteins were compatible with the labeling of a homogeneous population of binding sites at 37°C (Fig. 4). Corresponding affinities and B_{max} values are given in Table 3. The affinity of [3H]PSL was similar for all protein sources, and the K_d value obtained for recombinant human SV2A corresponded with the K_d obtained for the unlabeled compound using [3H]UCB30889 (Table 1).

UCB1244283 is a positive allosteric modulator of SV2A that increases the binding of BRV and LEV to the protein (Daniels et al., 2013). Use of the modulator (at 30 μM and at 4°C) had no effect on the B_{max} for [3H]PSL binding to the human SV2A protein in HEK membranes, but it reduced the affinity from 2.3 ± 0.2 nM (n = 3) to 3.90 ± 0.5 nM (P < 0.05, Student’s t test).

**Competition Experiments.** Competition experiments were performed on all human recombinant SV2 isoforms expressed in HEK cells and on human and rat cortex proteins using several SV2A ligands, as well as diazepam (Fig. 5). These experiments were performed with 0.9 nM [3H]PSL. Data were analyzed using sigmoidal dose-response fits with variable slope, and the resulting pIC_{50} values were transformed into pK_{i} values (Table 4). The affinity of the selective SV2A ligands—LEV, UCB30889, and BRV—was very low for both SV2B and SV2C labeled with [3H]PSL, resulting in incomplete competition curves at the concentration range used. This finding is in line with previous reports, demonstrating the selectivity of LEV and BRV for SV2A (Noyer et al., 1995; Gillard et al., 2011). Competition with PSL led to a complete displacement of [3H]PSL binding on all protein sources. For all human recombinant SV2 isoforms, the Hill slopes of the curve fits were not different from unity, and the obtained K_i values for PSL agreed with the K_d values of the radiolabeled compound.

In human and rat cortex, the competition curves of LEV, BRV, and UCB30889 fitted on the data using a sigmoidal dose-response curve with variable slope were shallower than those for PSL. The corresponding Hill coefficients ranged from −0.8 to −0.7 and reached significant difference from unity for LEV in both human and rat cortex (P < 0.01) and for UCB30889 and BRV in rat cortex (P < 0.01) (Table 4). The pronounced shallow profile of these competition curves allowed analysis of data with a model describing the binding to two independent populations of binding sites. At a radioligand concentration of 0.9 nM, the result fit with 85% of the binding sites having an affinity similar to that on recombinant human SV2A, and the remaining sites displaying an affinity in the low millimolar range. The latter proportion of binding sites most likely represents the SV2B component, given the very low presence of SV2C in the cortex.

### Effects in Selectivity Studies

Selectivity of PSL for its therapeutic targets was determined using radioligand binding, receptor activation and electrophysiological studies.

In radioligand studies, PSL at 10 μM lacked significant effects (>50%) on a wide variety of molecular targets, including ligand-gated and G-protein-coupled receptors, ion channels, transporters, and enzymes. The only significant effect was at the BZD binding site of the GABA_{A}R (87% inhibition), confirming the profile described already here. Approximately 50% inhibition of binding to the human neurokinin NK2 receptor was also observed and subsequently confirmed in a concentration-response study with a pIC_{50} of 5.

In receptor activation assays, PSL at concentrations up to 30 μM failed to elicit release of any of the tested cytokines from human peripheral blood mononuclear cells, indicating a lack of activity on TLR 2 and 4. In electrophysiological studies, PSL at 10 μM had no significant effect on any of the classic AED targets such as voltage-gated ion channels or glutamatergic receptors.

### Activity at Recombinant GABA_{A} Receptors

In the recombinant human α1β2γ2 GABA_{A}R subtype, application of GABA resulted in activation of Cl⁻ currents...
with an EC$_{50}$ of 15 mM (data not shown). To evaluate the effects of drugs on these GABA-evoked Cl$^-$ currents, an agonist concentration corresponding to its EC$_{20}$ (5 mM) was selected.

PSL, in a concentration range of 1 nM–30 mM, when added alone for 5 minutes during preincubation, did not significantly change basal Cl$^-$ currents compared with control (DMSO 0.5%, data not shown) but potentiated Cl$^-$ currents evoked by 5 mM GABA. Potentiation of GABA-induced Cl$^-$ currents was dose-dependent with an EC$_{50}$ of 137 nM and a maximal effect reaching 167% (Fig. 6).

The relative efficacy of PSL in potentiating GABA$_{ARC}$ Cl$^-$ currents was compared with that of zolpidem, a reference drug included in each experiment. Zolpidem is a full agonist at the BZD site and potentiates GABA [EC$_{20}$] with a maximal efficacy at 1 mM. The relative efficacy of PSL at 10 mM was 44% ± 16% compared with the maximal response to zolpidem defined as 100%.

**Discussion**

PSL was developed in a rational drug-discovery program initiated to develop a molecule with a novel mode of action aimed at the treatment of patients with drug-resistant epilepsy. Results of experiments described here confirm that PSL is a high-affinity pan-SV2 ligand, and it acts as a low-affinity partial agonist at the BZD site of GABA$_{AR}$s. Profiling studies also confirmed the lack of effect on typical AED targets, such as ion channels and glutamate receptors, as well
higher affinity for SV2A (Kd 1.5 nM) than for SV2B (Kd isoforms was also reflected in kinetic data. [3H]PSL dissociation kinetics were monophasic at human recombinant SV2A and interacting with SV2B and SV2C only at concentrations 100-fold higher than that at which they interacted with SV2A. This finding was also consistent with the lack of binding of a LEV derivative and of BRV in mouse brain tissue lacking SV2A (Lynch et al., 2004). The high affinity of [3H]PSL for all isoforms but more complex in human and rat cortex, most likely owing to the labeling of a relatively low fraction of SV2B and SV2A at 0.9 nM [3H]PSL. At this concentration, relatively more SV2A binding sites are labeled since [3H]PSL has a 4-fold higher affinity for SV2A (Kd 1.5 nM) than for SV2B (Kd 6.3 nM). Labeling of only a small proportion of SV2B in both human and rat cortex is supported by results of competition experiments; SV2C labeling was not anticipated given its restricted expression in the cortex (see the following). Results with LEV and BRV demonstrated labeling of approximately 85% of the binding sites with affinities similar to that at human recombinant SV2A. Finally, both SV2A and SV2C labeling in the cortex is supported by the observation that the B\text{max} values for [3H]PSL were approximately twice as high as those observed for SV2A-selective ligands (Gillard et al., 2003, 2011). Results do not allow an accurate prediction of the SV2A/B ratio in the cortex because differences in the labeling of both isoforms in native versus recombinant expression systems cannot be excluded. Overall, results are consistent with the interaction of PSL with all three SV2 isoforms and suggest that it may be a useful ligand in further characterization of these proteins.

The roles of SV2B and SV2C in the pathophysiology of epilepsy remain unknown. Few reports have addressed the role of SV2B since its distribution in the mammalian brain partly overlaps with that of SV2A (Bajjalieh et al., 1993, 1994). SV2B\text{−/−} mice do not show phenotypic abnormalities, and electrophysiological studies on cultured neurons from these mice do not reveal any obvious effects on neurotransmission (Janz et al., 1999a; Chang and Südhof, 2009; Venkatesan et al., 2012). In a recent study, SV2C expression was strongest in the basal ganglia and more restricted in the cortex of rodent, rhesus macaque, and human brain (Dunn et al., 2019), consistent with results from previous rodent studies (Janz and Südhof, 1999b; Dardou et al., 2011). In the human brain, SV2C was highly colocalized with the GABA transporter in the striatum, substantia nigra, and ventral tegmental area (Dunn et al., 2019). SV2C expression was weak or absent in the hippocampus at autopsy controls, but it increased in biopsies from patients with temporal lobe epilepsy owing to mesial temporal sclerosis; in contrast, SV2A and SV2B expression as a variety of other central nervous system targets, including ligand-gated and G-protein–coupled receptors, transporters and enzymes.

PSL is the first ligand that interacts with all three SV2 isoforms. In saturation and competition studies, [3H]PSL displayed nanomolar affinity for SV2A, SV2B, and SV2C. This finding was in contrast to LEV and BRV, both displaying marked selectivity for SV2A and interacting with SV2B and SV2C only at concentrations 100-fold higher than that at which they interacted with SV2A. This finding was also consistent with the lack of binding of a LEV derivative and of [3H]BRV in mouse brain tissue lacking SV2A (Lynch et al., 2004; Gillard et al., 2011). The high affinity of [3H]PSL for all isoforms was also reflected in kinetic data. [3H]PSL dissociation kinetics were monophasic at human recombinant SV2 isoforms but more complex in human and rat cortex, most likely owing to the labeling of a relatively low fraction of SV2B and SV2A at 0.9 nM [3H]PSL. At this concentration, relatively more SV2A binding sites are labeled since [3H]PSL has a 4-fold higher affinity for SV2A (Kd 1.5 nM) than for SV2B (Kd 6.3 nM). Labeling of only a small proportion of SV2B in both human and rat cortex is supported by results of competition experiments; SV2C labeling was not anticipated given its restricted expression in the cortex (see the following). Results with LEV and BRV demonstrated labeling of approximately 85% of the binding sites with affinities similar to that at human recombinant SV2A. Finally, both SV2A and SV2C labeling in the cortex is supported by the observation that the B\text{max} values for [3H]PSL were approximately twice as high as those observed for SV2A-selective ligands (Gillard et al., 2003, 2011). Results do not allow an accurate prediction of the SV2A/B ratio in the cortex because differences in the labeling of both isoforms in native versus recombinant expression systems cannot be excluded. Overall, results are consistent with the interaction of PSL with all three SV2 isoforms and suggest that it may be a useful ligand in further characterization of these proteins.

The roles of SV2B and SV2C in the pathophysiology of epilepsy remain unknown. Few reports have addressed the role of SV2B since its distribution in the mammalian brain partly overlaps with that of SV2A (Bajjalieh et al., 1993, 1994). SV2B\text{−/−} mice do not show phenotypic abnormalities, and electrophysiological studies on cultured neurons from these mice do not reveal any obvious effects on neurotransmission (Janz et al., 1999a; Chang and Südhof, 2009; Venkatesan et al., 2012). In a recent study, SV2C expression was strongest in the basal ganglia and more restricted in the cortex of rodent, rhesus macaque, and human brain (Dunn et al., 2019), consistent with results from previous rodent studies (Janz and Südhof, 1999b; Dardou et al., 2011). In the human brain, SV2C was highly colocalized with the GABA transporter in the striatum, substantia nigra, and ventral tegmental area (Dunn et al., 2019). SV2C expression was weak or absent in the hippocampus at autopsy controls, but it increased in biopsies from patients with temporal lobe epilepsy owing to mesial temporal sclerosis; in contrast, SV2A and SV2B expression

<table>
<thead>
<tr>
<th></th>
<th>SV2A</th>
<th>SV2B</th>
<th>SV2C</th>
<th>Rat Cortex</th>
<th>Human Cortex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Association</td>
<td>n = 4</td>
<td>n = 3</td>
<td>n = 3</td>
<td>n = 3</td>
<td>n = 3</td>
</tr>
<tr>
<td>K_m (nM·^{-1}·min^{-1})</td>
<td>0.02 ± 0.01</td>
<td>0.02 ± 0.03</td>
<td>0.04 ± 0.03</td>
<td>0.01 ± 0.004</td>
<td>0.06 ± 0.01</td>
</tr>
<tr>
<td>t_{1/2} (min)</td>
<td>13.9 ± 2.1</td>
<td>4.7 ± 0.8</td>
<td>2.6 ± 0.2</td>
<td>12.4 ± 0.8</td>
<td>7.9 ± 0.7</td>
</tr>
<tr>
<td>Dissociation</td>
<td>n = 6</td>
<td>n = 3</td>
<td>n = 3</td>
<td>n = 3</td>
<td>n = 3</td>
</tr>
<tr>
<td>k_{off} (min^{-1})</td>
<td>0.02 ± 0.01</td>
<td>0.13 ± 0.02</td>
<td>0.20 ± 0.02</td>
<td>0.04 ± 0.01</td>
<td>0.04 ± 0.01</td>
</tr>
<tr>
<td>t_{1/2} (min)</td>
<td>29.0 ± 5.8</td>
<td>5.4 ± 0.9</td>
<td>3.6 ± 0.4</td>
<td>16.0 ± 0.4</td>
<td>17.3 ± 2.8</td>
</tr>
<tr>
<td>K_D (nM)</td>
<td>1</td>
<td>7</td>
<td>7</td>
<td>4</td>
<td>1</td>
</tr>
</tbody>
</table>

k_{off} is the dissociation kinetic constant; k_{on} is the association kinetic constant; and t_{1/2} is the association or dissociation half-time.

Fig. 4. Saturation binding curves of [3H]padsevonil on human cortex (left panel) and on human recombinant SV2C (right panel) expressed in HEK cells. Membrane preparations were incubated with increasing concentrations of [3H]padsevonil for 150 minutes at 37°C. Nonspecific binding (NSB) represents residual binding in the presence of 10 \mu M of padsevonil. Specific binding = total binding – NSB. Data are representative of three independent experiments.
levels were decreased (Crèvecœur et al., 2014). Since PSL has high affinity for all three SV2 isoforms, it could be postulated that binding to SV2B/C, in addition to SV2A, may contribute to broader, more sustained antiseizure effects.

PSL differs from SV2A-selective ligands not only in its affinity for SV2B and SV2C, but also in its interaction with SV2A, as suggested by the slow kinetics of [3H]PSL and the effect of the modulator, UCB1244283. BRV and LEV have
extremely fast kinetics: BRV’s dissociation $t_{1/2}$ is 20 seconds at 37°C (Gillard et al., 2011), and that of LEV is 30 seconds at 25°C (Noyer et al., 1995). $[^{3}H]$PSL dissociation $t_{1/2}$ from human SV2A was 30 minutes at 37°C. This slower off-rate was also seen in rat and human cortex, suggesting a predominance of SV2A in these tissues. The SV2A positive allosteric modulator, UCB1244283, increases both BRV and LEV binding, but by different mechanisms; an increase in the binding capacity for LEV and an increase in binding affinity and capacity for BRV (Wood and Gillard 2017). Allosteric modulation is typically associated with an increase in binding affinity; however, as a putative transporter of the major facilitator superfamily, SV2 can adopt different inward and outward facing conformations (Quistgaard et al., 2016), and with selective binding of some ligands to only one conformation, the presence of an allosteric modulator that stabilizes or induces that specific conformation could seemingly increase binding capacity. The modulator did not significantly increase $[^{3}H]$PSL binding but reduced its affinity for SV2A, suggesting that SV2A may exist in multiple conformational states that can be stabilized by the SV2A modulator and that the three ligands—$[^{3}H]$LEV, $[^{3}H]$BRV, and $[^{3}H]$PSL—interact differently with it. Although LEV and BRV exert their therapeutic activity via interaction with SV2A (Matagne et al., 2008), their effect on the protein remains unknown. Therefore, it is difficult to predict the functional consequences of the slow off-rate and the novel mechanism of interaction of PSL with SV2A. Given the evidence that antiseizure potency correlates with SV2A binding affinity (Noyer et al., 1995; Kaminski et al., 2008, 2009b; Gillard et al., 2011), it is plausible that such a high-affinity and long-lasting interaction could also lead to improved antiseizure efficacy.

Postsynaptically, PSL displayed low-to-moderate (micromolar) affinity for the BZD site of GABA$_A$Rs in human and rat brain membranes with no interspecies difference in potency. Results were similar in recombinant GABA$_A$R subtypes with $\alpha_1$, $\alpha_2$, and $\alpha_5$ subunits coexpressed with $\beta_2$ and $\gamma_2$ subunits. These subunits were chosen because they have been suggested to mediate many of the BZDs’ pharmacological effects (D’Hulst et al., 2009). In functional studies, PSL lacked any direct effect on recombinant $\alpha_1\beta_2\gamma_2$ GABA$_A$Rs, but it potentiated the effects of low GABA concentrations ($EC_{50}$, giving around 20% of the maximum GABA response) with a $pEC_{50}$ of approximately 7.0 (100 nM). This observation is in keeping with the known mechanism of action of many BZDs, positive allosteric modulators of GABA$_A$Rs that do not open the Cl$^-$ channel on binding, but increase the affinity for channel gating by GABA (Sigel and Steinmann, 2012). PSL’s relative efficacy compared with zolpidem was 44%, indicating that it acts as a partial agonist. PSL was designed specifically to act as a partial agonist in an effort to minimize the potential for induction of tolerance. BZDs have potent antiseizure effects; however, their long-term use is limited by sedation, tolerance, and the risk of dependence (Riss et al., 2008; Rudolph and Knoflach, 2011;loba and Kilgo., 2016). In epilepsy, tolerance is associated with a loss of antiseizure efficacy, a progressive increase in seizure frequency and severity, and an increased risk of withdrawal seizures, even if AEDs are kept at constant $pK_a$ values and Hill slopes of selective synaptic vesicle protein (SV2A ligands and diazepam for sites labeled with 0.9 nM $[^{3}H]$padsevonil on recombinant human SV2A/B/C and on human and rat cortex at 37°C. Data are presented as mean ± S.D. ($n = 3–10$) and were obtained from nonlinear regression analysis of untransformed raw data using a sigmoidal dose-response model with variable slope. Missing values could not be calculated because of incomplete competition curves as a result of compound solubility limits.

<table>
<thead>
<tr>
<th></th>
<th>Levetiracetam</th>
<th>Brivaracetam</th>
<th>UCB30889</th>
<th>Padsevonil</th>
<th>Diazepam</th>
</tr>
</thead>
<tbody>
<tr>
<td>$pK_a$ SV2A</td>
<td>5.2 ± 0.1</td>
<td>6.6 ± 0.1</td>
<td>6.7 ± 0.2</td>
<td>8.5 ± 0.1</td>
<td>&lt;5</td>
</tr>
<tr>
<td>SV2B</td>
<td>3.1 ± 0.04</td>
<td>&lt;4</td>
<td>-4</td>
<td>7.9 ± 0.1</td>
<td>&lt;5</td>
</tr>
<tr>
<td>SV2C</td>
<td>3.2 ± 0.1</td>
<td>4.2 ± 0.1</td>
<td>4.8 ± 0.2</td>
<td>8.5 ± 0.2</td>
<td>5.6 ± 0.1</td>
</tr>
<tr>
<td>Human cortex</td>
<td>5.3 ± 0.3</td>
<td>6.4 ± 0.2</td>
<td>6.7 ± 0.2</td>
<td>8.7 ± 0.1</td>
<td>5.9 ± 0.4</td>
</tr>
<tr>
<td>Rat cortex</td>
<td>5.0 ± 0.1</td>
<td>6.4 ± 0.1</td>
<td>6.6 ± 0.2</td>
<td>8.7 ± 0.1</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Hill slope</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human cortex</td>
<td>-0.71 ± 0.03</td>
<td>-0.68 ± 0.05</td>
<td>-0.74 ± 0.12</td>
<td>-0.99 ± 0.21</td>
<td>ND</td>
</tr>
<tr>
<td>Rat cortex</td>
<td>-0.76 ± 0.03</td>
<td>-0.74 ± 0.26</td>
<td>-0.79 ± 0.15</td>
<td>-0.94 ± 0.13</td>
<td>ND</td>
</tr>
</tbody>
</table>

ND, not determined.

Fig. 6. Padsevonil potentiates GABA-mediated Cl$^-$ currents in CHO cells stably expressing human $\alpha_1\beta_2\gamma_2$ GABA$_A$ receptor subunits (left panel) by acting as a partial agonist at the benzodiazepine site of the receptor (right panel; bar represents S.D.). Zolpidem, a full agonist, displays a maximal response at 1 $\mu$M defined as 100%.
maintenance doses (Riss et al., 2008; Ochoa and Kilgo, 2016). Traditional BZDs such as DZP act as full agonists at the BZD site; partial agonists, however, with lower intrinsic efficacy, could potentially be associated with a lower likelihood of tolerance (Rundfeldt and Löscher, 2014). Approaches to reduce the limitations of BZDs have focused on the development of subtype-selective agents or those with low intrinsic efficacy (Rudolph and Knoflach, 2011; Rundfeldt and Löscher, 2014).

In vivo binding data indicate 50% SV2A and BZD site occupancy at 0.2 and at 36 mg/kg, respectively, supporting in vitro results, with 100-fold lower PSL potency at the BZD site compared with SV2A. In the accompanying report, PSL is shown to be active in a variety of nonclinical seizure and epilepsy models in the 0.1–10 mg/kg dose range (Leclerq et al., 2019). This finding corroborates observations that moderate-to-high SV2 occupancy is associated with antiseizure activity and that low-level BZD site occupancy potentiates this effect (Kaminski et al., 2009a).

In conclusion, PSL is a first-in-class AED candidate with a presynaptic and postsynaptic mechanism of action. Studies described here have shown that PSL displays high affinity for the three SV2 isoforms, ranging from 1.5 to 6.3 nM, and low-to-moderate affinity for the GABAA/BZD site, where it acts as a partial agonist, and that this profile is maintained in vivo. Furthermore, the interaction of PSL with SV2A differs from that of LEV and BRV in that it displays a markedly slower dissociation rate, and its activity is not potentiated by an SV2A modulator. These additional properties may contribute to the highly active profile of PSL in nonclinical seizure and epilepsy models, including those where the SV2A-selective ligands, LEV and BRV, show limited or no activity (Leclerq et al., 2019).

Acknowledgments

We thank John Lambert, David Urbain, Marielle Martini, and Veronique Deleerq (UCB Pharma, Braine l’Alleud, Belgium) for skillful technical assistance; Barbara Pelgrims (UCB Pharma, Brussels, Belgium) for overseeing the development of the manuscript; and Azita Tofighy for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Brussels, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Braine l’Alleud, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Brussels, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Braine l’Alleud, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Brussels, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Braine l’Alleud, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Brussels, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Braine l’Alleud, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Brussels, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Braine l’Alleud, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Brussels, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Braine l’Alleud, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Brussels, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Braine l’Alleud, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Brussels, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Braine l’Alleud, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Brussels, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Braine l’Alleud, Belgium) for providing writing support, funded by skillful technical assistance; Barbara Pelgrims (UCB Pharma, Brussels, Belgium) for providing writing support, funded by skil...


Address correspondence to: Michel Gillard, UCB Pharma, Neurosciences Therapeutic Area, Chemin du Foriest, 1420 Braine l’Alleud, Belgium. E-mail: michel.gillard@ucb.com